LKT Labs

Biochemicals for Life Science Research

Cyclovirobuxine D

Cyclovirobuxine D

Product ID C9711
Cas No. 860-79-7
Purity ≥97%
Product Unit SizeCostQuantityStock
25 mg $128.00 In stock
100 mg $318.00 In stock
500 mg $1,086.00 In stock
Bulk Quote

Quicklinks

Description

Cyclovirobuxine D is originally found in Buxus and displays cardioprotective and anticancer activities. Cyclovirobuxine inhibits the viability of breast cancer cells, inhibiting phosphorylation of Akt and mTOR and inducing autophagy. This compound also shows benefit in the treatment of heart failure but may prolong the QT interval through inhibition of human ether-a-go-go-related (hERG) K+ channel currents. Additionally, cyclovirobuxine D decreases infarct size and venous thrombus size in animal models of myocardial ischemia.

Product Info

Cas No.

860-79-7
Purity

≥97%
Formula

C26H46N2O
Formula Wt.

402.66
IUPAC Name

C26H46N2O
Synonym

Bebuxine, Cyclovirobuxine
Melting Point

219-224°C
Appearance

White crystal

Shipping and Storage

Store Temp

4°C
Ship Temp

Ambient

Downloads

MSDS

C9711 MSDS PDF
Info Sheet

C9711 Info Sheet PDF

References

Lu J, Sun D, Gao S, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. PMID: 24758922.

Yu B, Fang TH, Lü GH, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77. PMID: 21575690.

Zhao J, Wang Q, Xu J, et al. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells. Eur J Pharmacol. 2011 Jun 25;660(2-3):259-67. PMID: 21497594.

Hu D, Liu X, Wang Y, et al. Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. Eur J Pharmacol. 2007 Aug 13;569(1-2):103-9. PMID: 17555743.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C1600

    Carcinoembryonic Antigen (605-613)

    Carcinoembryonic antigen epitope.

    ≥95%
  • V3213

    Vidarabine Monophosphate

    Nucleoside (adenosine) analog found in Tethyra ...

    ≥98.0%
  • V1869

    Verbascoside

    Phenylpropanoid found in Castilleja, Verbena, V...

    ≥98%
  • A3080

    AHU-377 Tris Salt

    LBQ657 prodrug; neprilysin inhibitor.

    ≥99%
  • M1752

    Men 10376

    Peptide; NK2 antagonist.

    ≥95%
  • Z161025

    β-Zearalenol

    Mycotoxin that has structural similarity to est...

    ≥98%
  • L589938

    LOXO-195

    Inhibitor of TRK.

    ≥99%
  • V0376

    Vatalanib Dihydrochloride

    VEGFR inhibitor.

    ≥98%
  • P0278

    Patulin

    Mycotoxin produced by Penicillum and Aspergillu...

    ≥98%
  • T3036

    Thienylhexyl Isothiocyanate

    Thienylbutyl ITC analog.

    ≥97%
  • P6818

    Prednisolone

    Cortisol derivative; glucocorticoid agonist.

    ≥98%
  • T2932

    Thiamphenicol Glycinate Hydrochloride

    Chloramphenicol derivative; protein translation...

    ≥98%
  • C294458

    Chlorzoxazone

    Centrally acting muscle relaxant.

    ≥99%
  • A5302

    Anastrozole

    Aromatase inhibitor.

    ≥99%
  • S8151

    Sumatriptan Succinate

    Tryptamine; 5-HT1B/1D agonist, TRPV1 antagonist...

    ≥99%
  • M1575

    7-Methyl-6-mercaptopurine

    Thiopurine antimetabolite; PRPP amidotransferas...

    ≥87%
  • C3214

    CID-797718

    Potential PKD binding agent.

    ≥99%
  • S0244

    Salsalate

    Salicylic acid prodrug, NSAID; weak COX-1/2 inh...

    ≥95%
  • D3229

    7,8-Dihydrokawain

    Kavalactone originally found in Piper methystic...

    ≥98%
  • A9914

    AZD-8055

    mTOR inhibitor.

    ≥98%